‘Synthesis’ Tagged Posts

Sulfanilamide synthesis step 1: synthesis of p-acetamidobenzene sulfonyl chloride /sensible

...

 

Synthesis of Asprin from Sodium Salicylate

 

Anavex scale synthesis of Anavex 2-73 for phase 1 Alzheimer’s Disease Study

 

Anavex Life Sciences Corp. is an emerging biopharmaceutical company discovering and developing novel drugs for the treatment of cancer and neurological diseases intervention such as Alzheimer’s, epilepsy and depression.

Athens, Greece (openPR) 30 January 2009

Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL) has signed an agreement with the organic chemistry Syntagon Services AB (“Syntagon”) for the scale-up production of its lead compound ANAVEX 2-73 for the treatment of Alzheimer’s disease. ANAVEX 2-73, a phase 1 trials in 2009 is planned.

“The agreement with Syntagon another important and significant step towards the development of ANAVEX 2-73 and the beginning of Phase 1 trials,” said Harvey lalach, President of ANAVEX. “We are very pleased with our progress to date with the compound to change the enormous potential and reverse the effects of Alzheimer’s disease. We look forward to continued success, as we show move in our planned Phase 1 trials satisfied. ”

ANAVEX plans for a Contract Research Organization (CRO) just grab for the implementation of Phase 1 trials.

During pre-clinical studies (in vitro and in vivo in mice) ANAVEX 2-73 showed powerful neuroprotective, anti-amnesic, anti-apoptotic, anti-oxidative and anti-spasmodic properties. It also showed an excellent safety profile and therapeutic activity at very low doses. The compound is a novel tetrahydrofuran that has a high affinity and selectivity to sigma-1 receptors and synergistic action with muscarinic receptors. Additional positive effects have been demonstrated on NMDA receptors.

Syntagon is a provider of synthetic organic chemistry services in Södertälje, Sweden. The company has produced drug candidates for use in clinical studies for a number of important customers in the pharmaceutical industry. Syntagon operates in accordance with applicable quality standards of the industry and is checked and approved by the competent regulatory authorities in regard to the development and manufacture of material for use in clinical studies.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (www.anavex.com) is an emerging biopharmaceutical company engaged in the discovery and development of novel drugs for the treatment of cancer and neurological diseases such as Alzheimer’s, epilepsy and depression. The company’s proprietary SIGMACEPTOR в„ў Discovery Platform involves rational design of drug compounds that fulfill certain criteria to unmet market needs and new scientific advances base. Selected agents exhibit high, non-exclusive affinity for sigma receptors, which are involved in the modulation of several cellular biochemical signaling pathways.

ANAVEX’s SIGMACEPTOR в„ў-N program involves the development of novel and original drug candidates that target neurological and neurodegenerative diseases (Alzheimer’s, epilepsy, depression, pain). The company’s leading drug candidates exhibit high, non-exclusive affinity for sigma receptors with strong evidence for anti-amnesic, neuroprotective, anti-apoptotic, anti-oxidative, anti-inflammatory, anticonvulsant, anti-depressant and anxiolytic properties. The company believes that oxidative stress, not amyloid-beta, the cause of Alzheimer’s disease. ANAVEX 1-41 and 2-73 ANAVEX modulate sigma receptors, a unique class of receptor molecules, to guard against oxidative stress and repair compromised cells by their effects. So far, have the advanced clinical stage of development, the compounds performed very well in generally accepted animal model of Alzheimer’s disease and underscore the company’s promise of new and alternative approach to the disease.

ANAVEX SIGMACEPTOR в„ў-C program involves the development of novel and original drug candidates targeting cancer. The company’s leading drug candidates exhibit high, non-exclusive affinity for sigma receptors with strong evidence for selective pro-apoptotic, anti-metastatic and low toxicity properties in various types of solid tumors such as colon, prostate, breast and lung cancer. ANAVEX 7-1037 has already demonstrated its ability to significantly reduce the growth of cancerous tumors in patient-derived xenografts during advanced pre-clinical studies delayed.

Forward-Looking Statements

The statements in this press release that are not strictly historical are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in such statements predicted the result of various factors, including the risks and uncertainties inherent in drug discovery and development, including, without limitation, the potential failure of development candidates through preclinical studies or pre-show safety and efficacy in clinical tests and the ability to IND or commence clinical studies needed. You are encouraged not to place undue reliance on these statements, which only the date of this press release. This caution is under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Life Sciences Corp. Anavex assumes no obligation to revise or update this press release to reflect events or circumstances after the date of this release is qualified.


For more information


Anavex Life Sciences Corp.

Research & Business Development

Shareholder & Media Relations

Toll Free: 1-866-505-2895

Outside of North America: +1 (416) 489-0092

www.anavex.com

###

clear = “all”

Synthesis of bupropion (wellbutrin)-Part II CHEM2050

 

Synthesis of Bupropion (Wellbutrin)-Part I CHEM2050